Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.7.3119

Predictive Role of Computer Simulation in Assessing Signaling Pathways of Crizotinib-treated A549 Lung Cancer Cells  

Xia, Pu (Department of Biochemistry and Molecular Biology, Basic Medical College, China Medical University)
Mou, Fei-Fei (Shijiazhuang Medical College)
Wang, Li-Wei (Institute of Biomedical Engineering, Chinese Academy of Medical Science)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.7, 2012 , pp. 3119-3121 More about this Journal
Abstract
Non-small-cell lung cancer (NSCLC) is a leading cause of cancer deaths worldwide. Crizotinib has been approved by the U.S. Food and Drug Administration for the treatment of patients with advanced NSCLC. However, understanding of mechanisms of action is still limited. In our studies, we confirmed crizotinib-induced apoptosis in A549 lung cancer cells. In order to assess mechanisms, small molecular docking technology was used as a preliminary simulation of signaling pathways. Interesting, our results of experiments were consistent with the results of computer simulation. This indicates that small molecular docking technology should find wide use for its reliability and convenience.
Keywords
Lung cancer; crizotinib; apoptosis; computer simulation; Smad3;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
2 Daopin S, Piez KA, Ogawa Y, et al (1992). Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. Science, 257, 369-73.   DOI
3 Greenlee RT, Murray T, Bolden S, et al (2000). Cancer statistics, 2000. CA Cancer J Clin, 50, 7-33.   DOI   ScienceOn
4 Hallberg B, Palmer RH (2010). Crizotinib--latest champion in the cancer wars? N Engl J Med, 363, 1760-2.   DOI   ScienceOn
5 Janku F, Stewart DJ, Kurzrock R (2010). Targeted therapy in non-small-cell lung cancer -- is it becoming a reality? Nat Rev Clin Oncol, 7, 401-14.   DOI
6 Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703.   DOI
7 McDermott U, Iafrate AJ, Gray NS, et al (2008). Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res, 68, 3389-95.   DOI
8 Lam WK, White NW, Chan-Yeung MM (2004). Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis, 8, 1045-57.
9 Lengauer T, Rarey M (1996). Computational methods for biomolecular docking. Curr Opin Struct Biol, 6, 402-6.   DOI
10 Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.   DOI   ScienceOn
11 Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.   DOI   ScienceOn
12 Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11.   DOI   ScienceOn
13 Qin BY, Lam SS, Correia JJ, et al (2002). Smad3 allostery links TGF-beta receptor kinase activation to transcriptional control. Genes Dev, 16, 1950-63.   DOI   ScienceOn
14 Taylor RD, Jewsbury PJ, Essex JW (2002). A review of protein-small molecule docking methods. J Comput Aided Mol Des, 16, 151-66.   DOI
15 Schmierer B, Hill CS (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol, 8, 970-82.   DOI
16 Subramanian J, Govindan R (2008). Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol, 9, 676-82.   DOI
17 Sukits SF, Lin LL, Hsu S, et al (2001). Solution structure of the tumor necrosis factor receptor-1 death domain. J Mol Biol, 310, 895-906.   DOI
18 Wang Z, Canagarajah BJ, Boehm JC, et al (1998). Structural basis of inhibitor selectivity in MAP kinases. Structure, 6, 1117-28.   DOI
19 Xu ZY, Blot WJ, Xiao HP, et al (1989). Smoking, air pollution and the high rates of lung cancer in Shenyang, China. J Natl Cancer Inst, 81, 1800-6.   DOI
20 Yang JM (2004). Development and evaluation of a generic evolutionary method for protein-ligand docking. J Comput Chem, 25, 843-57.   DOI
21 Zhou S, Buckhaults P, Zawel L, et al (1998). Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA, 95, 2412-6.   DOI
22 Yang JM, Chen CC (2004). GEMDOCK: a generic evolutionary method for molecular docking. Proteins, 55, 288-304.   DOI